English News

  • youtube
  • facebook
  • twitter

2DG: DCGI Approves New Anti-COVID19 Oral Drug 2-DG developed by DRDO

Defence Research and Development Organisation (DRDO) developed anti-Covid oral drug laboratory has been granted emergency use approval by the Drug Controller General of India (DCGI). Called as the 2-deoxy-D-glucose (2-DG), the oral drug is developed by Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories. It will be used as an adjunct therapy in moderate cases of hospitalised COVID19 patients to reduce their supplemental oxygen dependence. Here's all you need to know about it!